GSK-4716 is a selective agonist of the estrogen-related receptor gamma (ERRγ). It is primarily researched for its potential therapeutic applications in oncology, where it modulates pathways involved in cancer cell proliferation and survival. Studies suggest that it may be effective in targeting specific dysregulated pathways in various types of cancer, potentially leading to reduced tumor growth and improved patient outcomes. Additionally, GSK-4716 is being explored for its role in combination therapies to enhance the efficacy of existing cancer treatments. Its development is still in the preclinical or early clinical stages, with ongoing research into its safety, efficacy, dosage, and long-term effects.